title: The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study.
abstract: In order to determine the role of levels of acute phase proteins (APPs) for the development of amyloidosis in familial Mediterranean fever (FMF) patients, the levels of serum amyloid A (SAA), C reactive protein (CRP), fibrinogen and erythrocyte sedimentation rate were measured in paired sera of 36 FMF patients during and in between acute attacks, 39 of their healthy parents (obligate heterozgotes), and 15 patients with FMF associated amyloidosis. To compare the levels of APPs, 39 patients with chronic infections or inflammatory diseases who may develop secondary amyloidosis, 20 patients with acute infections who are known to have elevated acute phase response but will never develop amyloidosis and 19 healthy controls were included. The median levels of all APPs are increased in the patients with FMF during attacks and a significant decrease was observed after the attack was over. The level of SAA was above reference range in all FMF patients during the attack free period and the level of at least one other APP was also above normal in 64% of the patients. Both CRP and SAA levels were found to be higher in obligate heterozygotes compared to controls. The levels of SAA in patients with FMF during the attack-free period, obligate heterozygotes and patients with FMF-amyloidosis were found to be similar. The levels in each group were found to be higher than SAA levels found in healthy controls yet lower than the levels measured in the patients with acute infections and patients with chronic inflammation or chronic infections. In conclusion, our results show that SAA level reflects subclinical inflammation with high sensitivity but its value for the prediction of amyloid formation process seems to be low.
authors.affiliation: Department of Pediatric Nephrology, Ankara University Faculty of Medicine, 38. Cadde, Mehmet Cakir Apt. 5/20, Cukurambar, Ankara, Turkey.
authors.forename: F
authors.initials: F
authors.lastname: Yalçinkaya
authors.forename: N
authors.initials: N
authors.lastname: Cakar
authors.forename: B
authors.initials: B
authors.lastname: Acar
authors.forename: E
authors.initials: E
authors.lastname: Tutar
authors.forename: H
authors.initials: H
authors.lastname: Güriz
authors.forename: A H
authors.initials: AH
authors.lastname: Elhan
authors.forename: S
authors.initials: S
authors.lastname: Oztürk
authors.forename: A
authors.initials: A
authors.lastname: Kansu
authors.forename: E
authors.initials: E
authors.lastname: Ince
authors.forename: S
authors.initials: S
authors.lastname: Atalay
authors.forename: N
authors.initials: N
authors.lastname: Girgin
authors.forename: U
authors.initials: U
authors.lastname: Doğru
authors.forename: D
authors.initials: D
authors.lastname: Aysev
authors.forename: M
authors.initials: M
authors.lastname: Ekim
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000686:Amyloidosis / Q000097:blood* / Q000453:epidemiology*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D010505:Familial Mediterranean Fever / Q000097:blood* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D012307:Risk Factors; D000685:Serum Amyloid A Protein / Q000378:metabolism
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D000685:Serum Amyloid A Protein